$heff's $tation of $tocks & $olid DD

[$heff]

MSTX..$.51..DD Post here. MSTX has a Market Cap $50.90M. Their Total Cash $53.5M = Cash Per Share $0.52. Debt is $0. This stock is trading below cash per share. $.40 low and $.82 high.

MSTX Ownership Chart from 3/30 to 6/30 Ownership up over 826% over past quarter. http://whalewisdom.com/stock/mstx

Franklin Resources Form 13G on 7/10/13 Filed a 10.7% Ownership.. http://bit.ly/18cYiSP
Sabby Management Form 13G on 6/25/13 Filed a 10% Ownership.. http://bit.ly/14MR6I6
Great Pt. Partner s Form 13G on 6/24/13 Filed a 9% Ownership .. http://bit.ly/15lDN02






MSTX trading at cash w ph 3 SCD asset with HIGH prob of stat sig, Orphan due for ALI in near-term. http://t.co/xpvWzOzaNP

Nice evaluation of MST-118 EPIC trial. This Ph 3 redesign (Peds only) sets this up for huge win ala $ACAD http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.pdf

http://finance.yahoo.com/news/mast-therapeutics-present-leerink-swann-120000758.html

Public Offering of Units on June 14th: http://yhoo.it/12wVmsv

http://www.masttherapeutics.com/company/ceo-blog/

http://www.veracast.com/bio/investorforum2013/main/events/1123_mastth/pdf/Mast_Therapeutics.pdf

http://www.veracast.com/webcasts/bio/investorforum2013/47112306857.cfm

2 Bold Speculative Plays In Biotech With Major Upside http://stks.co/blUd

http://www.analystratings.net/stocks/NASDAQ/mstx
-Cantor Fitgerald with a Buy rating
-Canaccord with a Buy rating $3 target price.
Canaccord like Mast Therapeutics on sickle cell potential
seekingalpha.com/f/n/s4qo
• Canaccord starts Mast Therapeutics (MSTX +15%) at Buy.
• Analyst Ritu Baral likes MST-188's (Orphan designation in Europe) chances in sickle cell, and says EPIC "is well designed enough to to support FDA and EMA approval by itself if ... successful." Expect read-out in 2016.
• Baral sees U.S. market launch in 2017 and peak sales of around $400M by 2023.
• Price target is $3, which, even counting this morning's double-digit gains, translates into a 477% upside.
Key objectives for the remainder of 2013 include:
http://yhoo.it/1aOtcBY
• Announcing results from the thorough QT/QTc study of MST-188, expected mid-year;
• Soliciting FDA input on our planned phase 2 study in acute limb ischemia, expected in the third quarter;
• Announcing results of nonclinical studies evaluating the physiologic significance of TEG results observed in prior nonclinical studies funded by the Defense Advanced Research Projects Agency (DARPA) Surviving Blood Loss (SBL) program, expected in the second half of the year;
• Initiating a microvascular blood flow sub-study in EPIC, expected in the fourth quarter;
• Initiating a phase 2 clinical proof-of-concept study of MST-188 in acute limb ischemia, expected in late 2013/early 2014;
• Obtaining orphan drug designation for MST-188 for acute limb ischemia;
• Submitting application(s) to request funding from the U.S. government to conduct a phase 2 clinical proof-of-concept study with MST-188 for resuscitation of shock following major trauma; and
• Filling patent applications claiming key aspects of our proprietary manufacturing process.


NPR News: Sickle Cell Anemia Is On The Rise http://n.pr/15C1ql7 New treatments can help as Mast Therapeutics is running a phase 3 trial.